Stockreport

Cellectar Reports Positive Phase 2 Interim Data for CLR 131 in Relapsed/Refractory DLBCL Patients

Cellectar Biosciences, Inc.  (CLRB) 
Last cellectar biosciences, inc. earnings: 11/12 08:00 am Check Earnings Report
US:NASDAQ Investor Relations: investor.cellectar.com
PDF MADISON, Wis., July 18, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences (Nasdaq:CLRB), a clinical stage biopharmaceutical company focused on the discovery, development [Read more]